Recognizing Hematology, Oncology, and Emergency Drugs
A teaching sequence for recognizing common hematology, oncology, anticoagulant, antiplatelet, emergency, and reversal drugs by class and typical clinical association.
Anticoagulants, Antiplatelets, and Reversal
Anticoagulants and antiplatelets
Start by identifying what each class affects. Anticoagulants act on the clotting cascade; antiplatelets reduce platelet clumping. Both reduce clot formation and can increase bleeding risk, but they are not interchangeable.
Heparin and enoxaparin: Heparins used for anticoagulation for venous clots; enoxaparin is commonly given by injection.
Warfarin: Oral vitamin K antagonist associated with PT/INR monitoring.
Apixaban, rivaroxaban, and edoxaban: Oral direct factor Xa inhibitors.
Dabigatran: Oral direct thrombin (factor IIa) inhibitor.
Aspirin: Antiplatelet that inhibits platelet COX-1; associated with arterial clot prevention.
Clopidogrel, prasugrel, ticagrelor, and cangrelor: P2Y12-receptor antiplatelets, often associated with acute coronary syndromes or coronary stents.
Eptifibatide, tirofiban, and abciximab: IV glycoprotein IIb/IIIa inhibitors used in selected acute coronary settings.
A useful contrast: warfarin and heparin are anticoagulants; aspirin and clopidogrel are antiplatelets. Among the oral direct anticoagulants listed, apixaban, rivaroxaban, and edoxaban inhibit factor Xa, while dabigatran inhibits thrombin.
Reversal matches
Vitamin K reverses warfarin effect. Protamine reverses unfractionated heparin, but reverses low-molecular-weight heparin less completely. Idarucizumab is the specific reversal agent for dabigatran. These are recognition matches, not instructions for treatment.
Hematologic Drugs by Their Main Effect
Hematologic drugs by their main effect
A practical way to sort these drugs is to ask which blood component or process they affect.
Promote red-cell production: Epoetin alfa and darbepoetin alfa are erythropoiesis-stimulating agents associated with selected anemia treatment.
Promote neutrophil production: Filgrastim and pegfilgrastim are G-CSF agents, commonly associated with chemotherapy-related neutropenia.
Increase platelet production: Eltrombopag is a thrombopoietin-receptor agonist used for selected low-platelet conditions.
Replace iron: Ferrous sulfate and other oral iron salts replace iron in iron deficiency.
Remove excess iron: Deferasirox is an iron chelator used for iron overload, including after repeated transfusions.
Sickle-cell disease: Hydroxyurea is an antimetabolite associated with reducing painful crises.
Slow clot breakdown: Tranexamic acid is an antifibrinolytic that helps reduce bleeding by slowing clot breakdown.
The production-based memory distinction is epoetin → red cells; filgrastim → neutrophils; eltrombopag → platelets. Keep this separate from iron drugs: ferrous sulfate replaces deficient iron, whereas deferasirox is used when iron is in excess.
Recognizing Oncology Drug Classes
Recognizing oncology drug classes
Classify a drug first, then use the stated cancer association as a matching clue. A class alone does not establish a drug’s exact indication: use depends on cancer type, biomarkers, and the treatment plan.
Cyclophosphamide, doxorubicin, cisplatin, methotrexate, and 5-fluorouracil (5-FU): Cytotoxic chemotherapy drugs that damage or inhibit rapidly growing cancer cells; each has distinct uses and toxicities.
Imatinib: Targeted tyrosine-kinase inhibitor classically associated with BCR-ABL–positive chronic myeloid leukemia; also used for some other cancers.
Trastuzumab: HER2-directed monoclonal antibody associated with HER2-positive cancers, especially breast and gastric cancer.
Tamoxifen, anastrozole, and letrozole: Endocrine therapies for hormone-receptor–positive breast cancer. Tamoxifen blocks estrogen receptors; anastrozole and letrozole inhibit aromatase.
Pembrolizumab and nivolumab: PD-1 immune-checkpoint inhibitors (immunotherapy) used across selected cancers.
Rituximab: CD20-directed monoclonal antibody associated with B-cell malignancies and some immune-mediated conditions.
This classification helps distinguish broad approaches: cytotoxic chemotherapy targets rapidly growing cancer cells; targeted treatments are linked to targets such as BCR-ABL or HER2; endocrine therapies act through hormone-related mechanisms; and pembrolizumab and nivolumab are immune-checkpoint inhibitors. These broad labels are a starting point for recognition, not a substitute for the specific treatment plan.
Emergency Drugs and Their Contexts
Emergency drugs and their contexts
Use these pairings for recognition, not as a treatment protocol. Actual use depends on the patient, contraindications, and current clinical guidelines.
Epinephrine: First-line emergency drug for anaphylaxis; also used in cardiac-arrest algorithms.
Naloxone: Reverses opioid effects in suspected opioid overdose. Emergency care is still needed after administration.
Atropine: Associated with symptomatic bradycardia.
Adenosine: Rapid treatment associated with certain regular, narrow-complex supraventricular tachycardias.
Amiodarone: Antiarrhythmic used in cardiac-arrest algorithms for shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.
Alteplase (tPA): Thrombolytic used in carefully selected clot-related emergencies.
Keep the associations specific: the source identifies particular rhythm contexts for atropine, adenosine, and amiodarone, rather than presenting them as interchangeable drugs for any abnormal rhythm. Likewise, alteplase is for carefully selected emergencies, not a general response to every clot.